Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
JV-001
- Development stage
- Phase 1
- Lead developer
- Juvensis Therapeutics
- Modality
- Gene Therapies
- Administration
- Percutaneous
01
Overview
JV-001 is a gene therapy developed for the treatment of heart failure due to dilated cardiomyopathy. It is an adeno-associated viral vector (AAV9) expressing a modified telomerase protein-telomerase reverse transcriptase (TERT), driven by a cardiac troponin T promoter (cTnT). The therapy aims to address the accelerated telomere shortening observed in cardiomyocytes during cardiac dysfunction, which leads to DNA damage. JV-001 targets telomeric ends to potentially restore cardiac function in heart failure patients.
- Other names
- AAV9-cTnT-modTERTAAV-9-cTnT-modTERTAAV 9-cTnT-modTERT
02
Targets
TERT (Telomerase)
Beyond the preview
Go deeper on JV-001.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on JV-001.